Biotechnology Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Axsome Therapeutics, Inc. (AXSM) Investors of Class Action and Encourages Investors to Contact the Firm May 23, 2022
Biotechnology Positive Results from VISEN’s Phase 3 Trial of Once-Weekly TransCon hGH in China Consistent with Ascendis Pharma’s Phase 3 Height Trial May 23, 2022
Biotechnology Ascendis Pharma A/S Announces New Commercial Endocrinology Leadership Appointments May 23, 2022
Biotechnology US FDA Accepts for Review Biohaven’s New Drug Application (NDA) Filing of Intranasal Zavegepant for the Acute Treatment of Migraine May 23, 2022
Biotechnology Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose May 23, 2022
Biotechnology CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Axsome Investors of a Lead Plaintiff Deadline of July 12, 2022 May 23, 2022
Biotechnology AXSM ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 12, 2022 in the Class Action Filed on Behalf of Axsome Therapeutics, Inc. Limited Shareholders May 20, 2022
Search
Biotechnology
